Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China
INCHEON, Korea--(BUSINESS WIRE)--Feb 10, 2019--Samsung Bioepis Co., Ltd. today announced its expansion in mainland China through a licensing agreement with C-Bridge Capital. The ag…
